Global pharmacogenetics: Genetic substructure of Eurasian populations and its effect on variants of drug-metabolizing enzymes

Pharmacogenomics

Volumn 9, Issue 7, 2008, Pages 847-868

  Makeeva, Oksana ^a   Stepanov, Vadim ^a   Puzyrev, Valery ^a   Goldstein, David B ^b   Grossman, Iris ^b,c  

^a RESEARCH INSTITUTE OF MEDICAL GENETICS   (Russian Federation)

^b DUKE UNIVERSITY   (United States)

^c GLAXOSMITHKLINE   (United States)

Author keywords

Alu insertion; Caucasus populations; Drug metabolizing enzymes; P450; Personalized medicine; Pharmacogenetics; SNP

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 3A5; DNA; DRUG;

ARTICLE; ASIAN; CLINICAL DECISION MAKING; CONTROLLED STUDY; GENE FREQUENCY; GENE IDENTIFICATION; GENE INSERTION; GENE LOCUS; GENETIC CONSERVATION; GENETIC DISTANCE; GENETIC VARIABILITY; GENOTYPE; HUMAN; MATHEMATICAL COMPUTING; MOLECULAR EVOLUTION; PHARMACOGENETICS; POPULATION GENETIC STRUCTURE; POPULATION RESEARCH; RUSSIAN FEDERATION; SHORT TANDEM REPEAT; SINGLE NUCLEOTIDE POLYMORPHISM; ALLELE; CAUCASIAN; GENETICS; METABOLISM;

ALLELES; ASIAN CONTINENTAL ANCESTRY GROUP; CYTOCHROME P-450 ENZYME SYSTEM; DNA; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENE FREQUENCY; GENOTYPE; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; SIBERIA; VARIATION (GENETICS);

EID: 49949113945     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.9.7.847     Document Type: Article

References (73)

1. Wilkinson GR: Drug metabolism and variability among patients in drug response. N. Engl. J. Med. 352, 2211-2221 (2005).
2. Meyer UA, Zanger UM: Molecular mechanisms of genetic polymorphisms of drug metabolism. Annu. Rev. Pharmacol. Toxicol. 37, 269-296 (1997).
3. Gaedigk A, Gotschall RR, Forbes NS, Simon SD, Kearns GL. Leeder JS: Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency data. Pharmacogenetics 9, 669-682 (1999).
4. Kirchheiner J, Nickchen K, Bauer M et al.: Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol. Psychiatry 9, 442-473 (2004).
5. de Leon J, Armstrong SC, Cozza KL: The dosing of atypical antipsychotics. Psychosomatics 46, 262-273 (2005).
6. Aquilante CL, Langaee TY, Lopez LM et al.: Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1. and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements. Clin. Pharmacol. Ther. 79, 291-302 (2006).
7. Marsh S, van Booven DJ, McLeod HL: Global pharmacogenetics: giving the genome to the masses. Pharmacogenomics 7(4), 625-631 (2006).
8. Garte S, Gaspari L, Alexandrie AK et al.: Metabolic gene polymorphism frequencies in control populations. Cancer Epidemiol. Biomarkers Prev. 10, 1239-1248 (2001).
9. Johns MB, Paulus-Thomas JE: Purification of human genomic DNA from whole blood using sodium perchlorate in place of phenol: Anal. Biochem. 180, 276-278 (1989).
10. Livak KJ: Allelic discrimination using fluorogenic probes and the 5′ nuclease assay. Genet. Anal. 14, 143-149 (1999).
11. Stepanov VA, Spiridonova MG, Tadinova VN, Puzyrev VP: Analysis of genetic diversity of North Eurasian populations using autosomal microsatellite loci. Russ. J. Genet. 39(10), 1168-1174 (2003).
12. Khitrinskaia Ilu, Stepanov VA, Puzyrev VP et al.: Genetic peculiarity of the Yakut population as infered from the autosomal loci data. Mol. Biol. (Mosk). 37(2), 205-209 (2003).
13. Khitrinskaia Ilu, Stepanov VA, Pyzyrev VP: Analysis of Alu polymorphism, in Buryat populations. Russ. J. Genet. 37(11), 1306-1311 (2001).
14. Khitrinskaia Ilu, Stepanov VA, Puzyrev VP, Spiridonova MG, Voevoda MI: Genetic differentiation of the population of central Asia inferred from autosomal markers. Russ. J. Genet. 39(10), 1175-1184 (2003).
15. Stepanov VA, Spiridonova MG, Puzyrev VP: Comparative phylogenetic study of native north Eurasian populations using a panel of autosomal microsatellite loci. Russ. J. Genet. 11(39), 1326-1333 (2003).
16. Guo S, Thompson E: Performing the exact test of Hardy-Weinberg proportion for multiple alleles. Biometrics 48, 361-372 (1992).
17. Excoffier L, Laval G, Schneider S: Arlequin ver. 3.0: An integrated software package for population genetics data analysis. Evol. Bioinform. Online 1, 47-50 (2005).
18. Weir BS, Cockerham CC: Estimating F-statistics for the analysis of population structure. Evolution 38, 1358-1370 (1984).
19. Excoffier L, Smouse P, Quattro J: Analysis of molecular variance inferred from metric distances among DNA haplotypes: application to human mitochondrial DNA restriction data. Genetics 131, 479-491 (1992).
20. Weir BS: Genetic Data Analysis II: Methods for discrete population genetic data. Sinauer Assoc, Inc.: MA, USA, 1-445 (1996).
21. Smouse P, Long J, Sokal RR: Multiple regression and correlation extensions of the Mantel test of matrix correspondence. Syst. Zool. 35, 627-632 (1986).
22. Gaikovitch EA, Cascorbi I, Mrozikiewicz PM et al.: Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population. Eur. J. Clin. Pharmacol. 59, 303-312 (2003).
23. Pchelina SN, Sirotkina OV, Taraskina AE, Vavilova TV, Shwarzman AL, Schwartz EI: The frequency of cytochrome P450 2C9 genetic variants in the Russian population and their associations with individual sensitivity to warfarin therapy. Thromb. Res. 115(3), 199-203 (2005).
24. Allabi AC, Gala JL, Desager JP. Heusterspreute M, Horsmans Y: Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations. J. Clin. Pharmacol. 56, 653-657 (2003).
25. Arvanitidis K, Ragia G, Iordanidou M et al.: Genetic polymorphisms of drug-metabolising enzymes CYP2D6, CYP2C9, CYP2C19 and CYP3A5 in the Greek population. Fundam. Clin. Pharmacol. 21(4), 419-426 (2007).
26. Bozina N, Granic P, Lalic Z, Tramišak I, Lovric M, Stavljerdc-Rukavina A: Genetic polymorphisms of cytochromes P450: CYP2C9, CYP2C19, and CYP2D6 in Croatian population. Croat. Med. J. 44(4), 425-428 (2003).
27. Scordo MG, Caputi AP, D'Arrigo C, Fava G, Spina E: Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population. Pharmacol. Res. 50, 195-200 (2004).
28. Chang M, Dahl ML, Tybring G, Gotharson E, Bertilsson L: Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. Pharmacogenetics 5(6), 358-363 (1995).
29. Nowak MP, Sellers EM, Tyndale RF: Canadian Native Indians exhibit unique CYP2A6 and CYP2C19 mutant allele frequencies. Clin. Pharmacol. Ther. 64, 378-383 (1998).
30. Roh HK, Dahl ML, Tybring G, Yamada H, Cha YN, Bertilsson L: CYP2C19 genotype and phenotype determined by omeprazole in a Korean population. Pharmacogenetics 6, 547-551 (1996).
31. Shimizu T, Ochiai H, Asell F et al.: Bioinformatirs research on inter-racial difference in drug metabolism I. Analysis of frequencies of mutant alleles and poor metabolizers on CYP2D6 and CYP2C19. Drug Metab. Pharmacokinet. 18(1), 48-70 (2003).
32. Takakubo F, Kuwano A, Kondo I: Evidence that poor metabolizers of (S)-mephenytoin could be identified by haplotypes of CYP2C19 in Japanese. Pharmacogenetics 6, 265-267 (1996).
33. Yamada S, Onda M, Kato S et al.: Genetic differences in CYP2C19 single nucleotide polymorphisms among four Asian populations. J. Gastroenterol. 36, 669-672 (2001).
34. Andersson T, Flockhart DA, Goldstein DB et al.: Drug-metabolizing enzymes: evidence for clinical utility of pharmacogenomic tests. Clin. Pharmacol. Ther. 78(6). 559-581 (2005).
35. International HapMap Consortium: A haplotype map of the human genome. Nature 437, 1299-1320 (2005).
36. Gu S, Pakstis AJ, Li H, Speed WC, Kidd JR, Kidd KK: Significant variation in haplotype block structure but conservation in tagSNP patterns among global populations. Eur. J. Hum. Genet. 15(3), 302-312 (2007).
37. González-Neira A, Ke X, Lao O et al.: The portability of tagSNPs across populations: a worldwide survey. Genome Res. 16(3), 323-330 (2006).
38. Mitchell-Olds T, Willis JH, Goldstein DB: Which evolutionary processes influence natural genetic variation for phenotypic traits? Nat. Rev. 8, 845-856 (2007).
39. Kuehl P, Zhang J, Lin Y et al.: Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet. 27, 383-391 (2001).
40. Weir BS, Cockerham CC: Estimating F-statistics for the analysis of population structure. Evolution 38(6), 1358-1370 (1984).
41. Weir BS, Cardon LR, Anderson AD, Nielsen DM, Hill WG: Measures of human population structure show heterogeneity among genomic regions. Genome Res. 15, 1468-1476 (2005).
42. Akey JM, Zhang G, Zhang K, Jin L, Shriver MD: Interrogating a high-density SNP map for signatures of natural selection. Genome Res. 12, 1805-1814 (2002).
43. Schwarz UI: Clinical relevance of genetic polymorphisms in the human CYP2C9 gene. Eur. J. Clin. Invest. 33(Suppl. 2), 23-30 (2003).
44. Zhang X, Chen BC, Xiang FL et al.: Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation. Clin. Transplant. 19(5), 638-643 (2005).
45. de Leon J: AmpliChip CYP450 test: personalized medicine has arrived in psychiatry. Expert Rev. Mol. Diagn. 6, 277-286 (2006).
46. Lehmann DF, Medicis JJ, Franklin PD: Polymorphisms and the pocketbook: the cost-effectiveness of cytochrome P450 2C 19 genotyping in the eradication of Helicobacter pylori infection associated with duodenal ulcer. J. Clin. Pharmacol. 43(12), 1316-1323 (2003).
47. Matchar DB, Thakur ME, Grossman I et al.: Testing for cytochrome P450 polymorphisms in adults with non-psychotic depression treated with selective serotonin reuptake inhibitors (SSRIs). Evid. Rep. Technol. Assess (Full Rep.) 146, 1-77 (2007).
48. Grossman I, Liu Y, Walley N et al.: Pharmacogenetic analysis of antipsychotics: comprehensive analysis of pharmacokinetic variants. Presented at: 56th Annual Meeting of the American Society of Human Genetics (ASHC). New Orleans, LA, USA, 9-13 October 2006.
49. Bulletin Board: FDA releases final guidance for pharmacogenomic data. Pharmaconomics 6(3), 209 (2005).
50. Grossman I: Routine pharmacogenetic testing in clinical practice - dream or reality? Pharmacogenomics 8(10), 1449-1459 (2007).
51. Cascorbi J, Ackermann E, Sachse C, Brockmoller J, Roots I: A novel CYP2C9 intron 2T/C transition and linkage to mutations Leu359 and Cys144. Clin. Pharmacol. Ther. 63, 198 (1998).
52. Taube J, Halsall D, Baglin T: Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk over-anticoagulation in patients on long-term treatment. Blood 96, 1816-1819 (2000).
53. Garcia-Martin E. Martinez C, Ladero JM, Gamito FJ, Agundez JA: High frequency of mutations related to impaired CYP2C9 metabolism in a Caucasian population. Eur. J. Clin. Pharmacol. 57, 47-49 (2001).
54. Dorado P, Berecz R. Norberto MJ, Yasar U, Dahl ML, LLerena A: CYP2C9 genotypes and diclofenac metabolism in Spanish healthy volunteers. Eur. J. Clin. Pharmacol. 59, 221-225 (2003).
55. Yasar U, Eliasson E, Dahl ML, Johansson I, Ingelman-Sundberg M, Sjöqvist F: Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish. Biochem. Biophys. Res. Commun. 254(3), 628-631 (1999).
56. Gaedigk A, Casley WL, Tyndale RF, Sellers EM, Jurima-Romet M, Leeder LS: Cytochrome P.4502C9 (CYP2C9) allele frequencies in Canadian Native Indian and Inuit populations. Can. J. Physiol. Pharmacol. 79, 841-847 (2001).
57. Wang SL, Huang J, Lai MD, Tsai JJ: Detection of CYP2C9 polymorphism based on the polymerase chain reaction in Chinese. Pharmacogenetics 5, 37-42 (1995).
58. Nakai K, Habano W, Nakai K et al.: Ethnic differences in CYP2C9*2 (Arg144Cys) and CYP2C9*3 (I1e359Leu) genotypes in Japanese and Israeli populations. Life Sci. 78, 107-111 (2005).
59. Nasu K, Kubota T, Ishizaki T: Genetic analysis of CYP2C9 polymorphism in a Japanese population. Pharmacogenetics 7, 405-409 (1997).
60. Yoon YR, Shon JH, Kim MK et al.: Frequency of cytochrome P450 2C9 mutant alleles in a Korean population. Br. J. Clin. Pharmacol. 51, 277-280 (2001).
61. Aynacioglu AS, Sachse C, Bozkurt A et al.: Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population. Clin. Pharmacol. Ther. 66, 185-192 (1999).
62. van Schaik RHN, van der Heiden IP, van den Anker JN, Lindemans J: CYP3A5 variant allele frequencies in Dutch Caucasians. Clin. Chem. 48, 1668-1671 (2002).
63. Quaranta S, Chevaller D, Bourgarel-Rey V et al.: Identification by single-strand conformational polymorphism analysis of known and new mutations of the CYP3A5 gene in a French population. Toxicol. Lett. 164(2), 177-184 (2006).
64. King BP, Leathart JB, Mutch E, Williams FM, Daly AK: CYP3A5 phenotype-genotype correlations in a British population. Br. J. Clin. Pharmacol. 55(6), 625-629 (2003).
65. Gervasini G, Vizcaino S, Gasiba C, Carrillo JA, Benitez J: Differences in CYP3A5*3 genotype distribution and combinations with other polymorphisms between Spaniards and other Caucasian populations. Ther. Drug Monit. 27(6), 819-821 (2005).
66. Mirghani RA, Sayi J, Akilillu E et al.: CYP3A5 genotype has significant effect on quinine 3-hydroxylation in Tanzanians, who have lower total CYP3A activity than a Swedish population. Pharmacogenet. Genomics 16(9), 637-645 (2006).
67. Thompson EE, Kuttab-Boulos H, Witonsky D. Yang L, Roe BA, Di Rienzo A: CYP3A5 variation and the evolution of salt-sensitivity variants. Am. J. Hum. Genet. 75(6), 1059-1069 (2004).
68. Hustert E, Haberl M, Burk O et al.: The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 11(9), 773-779 (2001).
69. Balram C, Zhou Q, Cheung YB, Lee EJ: CYP3A5*3 and *6 single nucleotide polymorphisms in three distinct Asian populations. Eur. J. Clin. Pharmacol. 59(2), 123-126 (2003).
70. Wang HP, Xie JJ, Zhang ZY et al.: Study on polymorphisms of CYP3A5 gene and their clinical role, Zhonghua Yi Xue Yi Chuan Xue Za Zhi 22(4), 423-426 (2005).
71. Saeki M, Saito Y, Nakamura T et al.: Single nucleotide polymorphisms and haplotype frequencies of CYP3A5 in a Japanese population. Hum. Mutat. 21(6), 653 (2003).
72. Hiratsuka M, Takekuma Y, Endo N et al.: Allele and genotype frequencies of CYP2B6 and CYP3A5 in the Japanese population. Eur. J. Clin. Pharmacol. 58(6), 417-421 (2002).
73. Fukuen S, Fukuda T, Maune H et al.: Novel detection assay by PCR-RFLP and frequency of the CYP3A5 SNPs, CYP3A5*3 and *6, in a Japanese population. Pharmacogenetics 12(4), 331-334 (2002).